CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients.
Caroline BailleuxAntoine ArnaudJean-Sébastien FrenelSylvie ChabaudThomas BachelotBenoît YouLaëtitia StefaniClaire Garnier TixidreHélène SimonDominique Beal-ArdissonJean-Philippe JacquinFrancesco Del PianoAlain LortholaryClaudiu CorneaCharlotte GreilsamerRémy LargillierFabien BrocardEric LegouffeMustapha AtlassiAnne-Claire Hardy-BessardPierre-Etienne HeudelPublished in: Breast cancer (Tokyo, Japan) (2023)
The addition of AI to oral vinorelbine over oral vinorelbine alone in aromatase inhibitor-resistant metastatic breast cancer was associated with a non-significant improvement of PFS. Several unexpected serious adverse events were reported. Metronomic oral vinorelbine schedule, at 50 mg three times a week, requires close biological monitoring. The question of hormonal treatment and chemotherapy combination remains open.
Keyphrases
- phase ii
- open label
- clinical trial
- phase iii
- phase ii study
- placebo controlled
- metastatic breast cancer
- double blind
- squamous cell carcinoma
- small cell lung cancer
- study protocol
- machine learning
- minimally invasive
- radiation therapy
- artificial intelligence
- adipose tissue
- metabolic syndrome
- locally advanced
- deep learning
- combination therapy
- smoking cessation